Enoxacin

Enoxacin is a fluoroquinolone antibiotic.^1,2,3,4 It is active against clinical isolates of a variety of Gram-positive and Gram-negative bacteria, including S. aureus, E. coli, K. pneumoniae, P. aeruginosa, and S. marcescens (MIC₅₀s = 1, 0.12, 0.25, 0.5, and 1 mg/L, respectively).¹ Enoxacin inhibits S. aureus DNA gyrase supercoiling activity and topoisomerase IV DNA decatenation (IC₅₀s = 126 and 26.5 µg/ml, respectively).² It increases survival in mouse models of systemic S. aureus, E. coli, K. pneumoniae, P. aeruginosa, and S. marcescens infection with ED₅₀ values of 15.1, 2.2, 4.1, 120.3, and 7.6 mg/kg, respectively.³ Enoxacin (4 and 8 mg/kg per day) also reduces tumor growth in a 143B human osteosarcoma mouse xenograft model.⁴ Formulations containing enoxacin have previously been used in the treatment of urinary tract infections and gonorrhea.

WARNING This product is not for human or veterinary use.

1. Clarke, A.M., Zemcov, S.J., and Campbell, M.E. In-vitro activity of pefloxacin compared to enoxacin, norfloxacin, gentamicin and new β-lactams. J. Antimicrob. Chemother. 15(1), 39-44 (1985).

2. Takei, M., Fukuda, H., Kishii, R., et al. Target preference of 15 quinolones against Staphylococcus aureus, based on antibacterial activities and target inhibition. Antimicrob. Agents Chemother. 45(12), 3544-3547 (2001).

3. Ozaki, M., Matsuda, M., Tomii, Y., et al. In vivo evaluation of NM441, a new thiazeto-quinoline derivative. Antimicrob. Agents Chemother. 35(12), 2496-2499 (1991).

4. Luo, X., Liu, X., Tao, Q., et al. Enoxacin inhibits proliferation and invasion of human osteosarcoma cells and reduces bone tumour volume in a murine xenograft model. Oncol. Lett. 20(2), 1400-1408 (2020).